MGMT methylation status as a prognostic factor in anaplastic astrocytomas

被引：0
|
作者：
Tosoni, A. [1 ,2 ,3 ,4 ,5 ]
Franceschi, E. [1 ,2 ,3 ,4 ,5 ]
Ermani, M. [1 ,2 ,3 ,4 ,5 ]
Bacci, A. [1 ,2 ,3 ,4 ,5 ]
Volpin, L. [1 ,2 ,3 ,4 ,5 ]
Lombardo, L. [1 ,2 ,3 ,4 ,5 ]
Ravenna, G. [1 ,2 ,3 ,4 ,5 ]
Pinna, G. [1 ,2 ,3 ,4 ,5 ]
Poggi, R. [1 ,2 ,3 ,4 ,5 ]
Brandes, A. A. [1 ,2 ,3 ,4 ,5 ]
机构：
[1] Bellaria Maggiore Hosp, Bologna, Italy
[2] Azienda Hosp Univ, Padua, Italy
[3] Hosp Civile, Vicenza, Italy
[4] Azienda Hosp, Verona, Italy
[5] Policlin Modena, Modena, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2052
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Anaplastic astrocytomas: survival and prognostic factors in a surgical series
    Rogne, Siril G.
    Konglund, Ane
    Scheie, David
    Helseth, Eirik
    Meling, Torstein R.
    ACTA NEUROCHIRURGICA, 2014, 156 (06) : 1053 - 1061
  • [22] Anaplastic astrocytomas: survival and prognostic factors in a surgical series
    Siril G. Rogne
    Ane Konglund
    David Scheie
    Eirik Helseth
    Torstein R. Meling
    Acta Neurochirurgica, 2014, 156 : 1053 - 1061
  • [23] MGMT PROMOTER METHYLATION AS AN INDEPENDENT PROGNOSTIC FACTOR IN THE ABSENCE OF ALKYLATING CHEMOTHERAPY IN GLIOBLASTOMA
    Rivera, Andreana
    Pelloski, Christopher
    Gilbert, Mark
    Colman, Howard
    De La Cruz, Clarissa
    Aldape, Kenneth
    NEURO-ONCOLOGY, 2008, 10 (05) : 855 - 855
  • [24] MGMT promoter methylation is an independent prognostic factor in the absence of alkylating chemotherapy in glioblastoma
    Pelloski, C. E.
    Rivera, A. L.
    De La Cruz Guerrero, C.
    Aldape, K. D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : S9 - S9
  • [25] Impact of MGMT methylation status on 1p/19q intact anaplastic gliomas
    Franceschi, E.
    Tosoni, A.
    Ermani, M.
    Spagnolli, F.
    La Torre, L.
    Galzio, R. J.
    Pozzati, E.
    Talacchi, A.
    Benevento, F.
    Brandes, A. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [26] MGMT methylation status in glioblastomas multiforme
    Antonets, A. V.
    Yakovlenko, Y. G.
    Mordanov, S. V.
    Tushev, A. A.
    Moldovanov, V. A.
    Deribas, V. Y.
    Todorov, S. S.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2020, 28 (SUPPL 1) : 938 - 939
  • [27] Overexpression of c-erb B2 is a negative prognostic factor in anaplastic astrocytomas
    Sasha Gulati
    Borgny Ytterhus
    Unn S Granli
    Michel Gulati
    Stian Lydersen
    Sverre H Torp
    Diagnostic Pathology, 5
  • [28] TERT PROMOTER MUTATION IS A POOR PROGNOSTIC MARKER FOR GBMS AND INTERACTS WITH MGMT METHYLATION STATUS
    Arita, Hideyuki
    Yamasaki, Kai
    Nakamura, Taishi
    Shirahata, Mitsuaki
    Kobayashi, Keiichi
    Tamura, Kaoru
    Fukai, Junya
    Terakawa, Yuzo
    Mori, Kanji
    Nakamura, Hideo
    Yoshimoto, Koji
    Kanemura, Yonehiro
    Mukasa, Akitake
    Nagane, Motoo
    Ueki, Keisuke
    Komori, Takashi
    Nishikawa, Ryo
    Narita, Yoshitaka
    Ichimura, Koichi
    NEURO-ONCOLOGY, 2016, 18 : 108 - 108
  • [29] Prognostic prediction of glioblastoma by quantitative assessment of the methylation status of the entire MGMT promoter region
    Manabu Kanemoto
    Mitsuaki Shirahata
    Akiyo Nakauma
    Katsumi Nakanishi
    Kazuya Taniguchi
    Yoji Kukita
    Yoshiki Arakawa
    Susumu Miyamoto
    Kikuya Kato
    BMC Cancer, 14
  • [30] Impact of predictive impact of MGMT promoter methylation in malignant astrocytomas depends on the methylation subgroup.
    Wick, Wolfgang
    Kessler, Tobias
    Platten, Michael
    Meisner, Christoph
    Bamberg, Michael
    Herrlinger, Ulrich
    Happold, Caroline
    Weisang, Sarah
    Boelting, Hanna
    Steinbach, Joachim
    Reifenberger, Guido
    Sahm, Felix
    von Deimling, Andreas
    Wick, Antje
    Weller, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345